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To the Editor:
Epidemiological studies suggest that patients with asthma are not at an increased risk of severe coronavirus
disease 2019 (COVID-19) caused by the novel coronavirus severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) [1–3]. Recent studies indicate that the severity of COVID-19 in patients with asthma is
likely to depend on multiple factors. A type 2-low asthma phenotype, use of oral corticosteroids and severe
asthma could be aggravating factors, while maintenance treatment with inhaled corticosteroids (ICS) and
good asthma control are probably protective [4]. However, there is currently scarce information on the risk
associated with COVID-19 in subjects with severe asthma and/or the use of biologics. Since eosinopenia is
a biomarker for the severity of COVID-19 [5], the eosinophil depletion induced by anti-IL5 and anti-IL5
receptor blocking monoclonal antibodies raises concern in patients and their treating physicians. The
handful of case reports about patients using the monoclonal antibodies omalizumab [6], benralizumab [7]
or dupilumab for atopic dermatitis do offer a reassuring picture, but larger studies performed in patients
with asthma are urgently needed. In immune-mediated inflammatory diseases, such as rheumatoid
arthritis and psoriasis, treatment with biologics was not associated with worse COVID-19 outcomes [8].
Positioning papers and guidelines recommend asthma patients to maintain their regular treatments,
including asthma biologics for those who qualify for them [9, 10], but epidemiological or clinical research
data are scarce [1, 11].
The aim of our observational study was to evaluate the occurrence of COVID-19 in adult patients with
severe asthma, based on data from the Belgian Severe Asthma Registry (BSAR), and to assess whether
patients with severe asthma using biologics present an increased risk of severe COVID-19 as compared to
those who do not use these medications.
The BSAR, a prospective cohort of patients with severe asthma defined according to the European
Respiratory Society/American Thoracic Society criteria, has enrolled 1416 patients since 2009 [12, 13].
After obtaining the approval for an amendment from the BSAR’s central ethics committee (UZ Gent;
B67020084584), nine participating asthma centres contacted their patients. Of the 777 patients with severe
asthma (68% of patients with active follow-up in BSAR, i.e. with registry visits during the past 2 years)
that were contacted, 676 (87%) participated in this survey.
A standardised questionnaire was administered by phone or during outpatient visits and information
about symptoms suggestive of COVID-19, hospital admission for COVID-19 and diagnostic testing
through nasopharyngeal swab (PCR) or serology (SARS-CoV-2 IgG) was obtained. Patients were contacted
between 30 April and 8 July 2020. Until 24 April, the government policy in Belgium was to limit PCR
testing to healthcare workers or severe COVID-19 cases requiring hospitalisation. In case of milder
symptoms, patients were put in quarantine but were not tested. From 24 April onwards, a greater
proportion of samples were collected from symptomatic and asymptomatic people, as part of screening
programmes, for instance prior to an intervention or hospitalisation. The monoclonal antibodies available
for clinical use in severe asthma in Belgium are omalizumab, mepolizumab, benralizumab and reslizumab,
while dupilumab is not yet reimbursed for asthma.
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266 (39%) of the 676 participants experienced at least one symptom suggestive of COVID-19 during the
4 months preceding the survey. Dyspnoea (n=172; 25%), rhinorrhoea (n=116; 17%), productive cough
(n=107; 16%), headache (n=105; 16%) and chest pain (n=69; 10%), were the most frequently reported
symptoms. Only 43 patients (6%) mentioned fever and only 35 (5%) of the patients experienced sudden
olfactory and gustative dysfunction, symptoms that are considered quite specific for COVID-19 [14],
suggesting a low incidence of symptomatic COVID-19 in the study population.
Out of 676 patients, only 66 were tested by PCR on nasopharyngeal aspirates and nine (14%) tested
positive for SARS-CoV-2 (table 1). 40 (61%) PCR tests were performed because the patients presented
suggestive symptoms, whereas the remaining tests were done in the context of healthcare or contact
screenings. All the patients that had a positive PCR test had presented with suggestive symptoms. As the
national restrictions with regard to PCR testing might have led to an underestimation of the true incidence
of SARS-CoV-2 infection in patients with severe asthma in Belgium, serology testing to determine
SARS-CoV-2 IgG antibody levels was performed, at the discretion of the treating physician, in a subgroup
of patients that had presented a combination of symptoms suggestive of COVID-19. Positive IgG serology
was found in only eight out of 98 tested patients. Of note, three of these patients who showed positive
SARS-CoV-2 IgG had also demonstrated a positive PCR test. Because serology testing for COVID-19 only
became available for large-scale clinical use towards the end of our study period ( June 2020), the number
of cases identified by serology is probably also an underestimation of the true incidence. Overall, we
identified 14 patients with COVID-19 infection confirmed by either PCR and/or specific IgG (table 1). Of
these 14 patients, only five (all PCR-positive) had been hospitalised (with a short hospital stay ranging
from 2 to 8 days). None presented with a severe asthma exacerbation or required treatment with systemic
corticosteroids, admission to the intensive care unit, non-invasive ventilation, mechanical ventilation or
extracorporeal membrane oxygenation, and there were no deaths. Only three patients received
supplemental oxygen therapy (for 3 to 8 days). Chest computed tomography scan was performed in four
hospitalised severe asthma patients and revealed pulmonary consolidations in three patients. Patients with
confirmed COVID-19 reported a significantly higher median (interquartile range) number of symptoms
than the remainder of the study population (6 (3–10) versus 2 (1–3); p<0.000001). Of the 35 patients that
presented gustative or olfactory dysfunction, 24 were tested by means of PCR and/or serology and 10
(42%) were found positive, a finding that is consistent with these symptoms being considered more
specific for COVID-19 [14]. Importantly, there was no difference in incidence of COVID-19 between
severe asthma patients treated with biologics (anti-IgE or anti-IL5/anti-IL5R) and patients not receiving
any asthma biologic (p>0.05) (table 1), but as the number of confirmed cases is small, this has to be
interpreted cautiously. Recent use of oral corticosteroids (OCS) has been identified as a risk factor for
TABLE 1 Results of coronavirus disease 2019 (COVID-19) diagnostic testing and treatment of
confirmed COVID-19 patients according to severe asthma treatment group
No biologic Anti-IgE Anti-IL5 or anti-IL5R






PCR test for COVID-19
Not done 211 118 281
Positive 3 (1.2%) 0 6 (2%)
Negative 28 11 18
IgG test for COVID-19
Not done 241 99 238
Positive 0 4 (3.1%) 4 (1.3%)
Negative 1 26 63
Daily OCS n 20 (8.2%) 10 (7.8%) 28 (9.2%)
Median dose mg (prednisone equivalent) 4.5 5.0 5.0
Confirmed COVID-19 patients n 3 4 7
% of subgroup 1.2# 3.1# 2.3#
Hospitalisation n 1 0 4
Duration of hospitalisation days 5 NA 4.5 (range 2–8)
O2 therapy n 1 0 2
Duration of O2 therapy days 3 NA 5.5 (range 3–8)
NA: not applicable; OCS: oral corticosteroid. #: Chi-square test, p>0.05.
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COVID-19 related death [11], but in our cohort none of the 58 patients treated with maintenance OCS
(median prednisone dose of 5 mg) were diagnosed with COVID-19.
To the best of our knowledge, this study is among the first to investigate the risk and severity of COVID-19
in a large cohort of well-characterised patients with severe asthma. The findings indicated a low incidence of
COVID-19 infection in severe asthma patients (14 out of 676 patients; 2.1%). Nevertheless, it is difficult to
compare the incidence rate of confirmed COVID-19 cases in our BSAR cohort to the figure in the general
population. Analysis of blood samples from Belgian blood donors revealed a seroprevalence reaching up to
5.1% [15]. Our study showed that only 2.1% of patients with severe asthma in Belgium had positive PCR or
specific IgG to SARS-CoV-2 and that only 5% presented COVID-19-related symptoms. Whether this
relatively low incidence is due to those with severe asthma being more cautious than the general population
and complying better with social distancing and other hygienic measures, or whether it is due to (patho)
physiological features (type 2 inflammation) or beneficial effects of treatments such as ICS (the latter factors
being associated with lower angiotensin-converting enzyme 2 expression) [16] remains to be elucidated.
Whereas viral respiratory tract infections are the most important cause of asthma exacerbations, none of
the patients with confirmed COVID-19 in our BSAR cohort experienced an exacerbation. This is in line
with the recent publication by BEURNIER et al. [1] reporting that, among hospitalised patients with severe
pneumonia due to SARS-CoV-2 infection, patients with asthma were not overrepresented and did not
present with an asthma exacerbation. The national restrictions with regard to PCR testing and the
resulting possible underestimation of the true incidence of COVID-19 are a limitation of our study. Also,
the participation in the survey of severe asthma patients already participating in a registry might have
created some selection bias, limiting the generalisability of our data. On the other hand, the careful
characterisation of the patients in our cohort is a strength of this research.
In conclusion, among this cohort of adult patients with severe asthma, a small number of COVID-19 cases
was found, none of which resulted in death or a very severe disease course. Treatment with biologics for
severe allergic or severe eosinophilic asthma was not associated with a higher risk of SARS-CoV-2
infection nor with more severe COVID-19. These data support the current practice to continue treatment
with biologics in severe asthma during the COVID-19 pandemic.
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